Literature DB >> 18358909

Tocilizumab for rheumatoid and juvenile idiopathic arthritis.

Tim Bongartz1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18358909     DOI: 10.1016/S0140-6736(08)60428-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Tocilizumab: A new anti-rheumatic drug.

Authors:  Hisham S Abou-Auda; Walid Sakr
Journal:  Saudi Pharm J       Date:  2010-08-03       Impact factor: 4.330

2.  Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients.

Authors:  Jing Chen; Dan-Xue Zheng; Xing-Juan Yu; Hong-Wei Sun; Yi-Tuo Xu; Yao-Jun Zhang; Jing Xu
Journal:  Oncoimmunology       Date:  2019-08-15       Impact factor: 8.110

3.  Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells.

Authors:  Na-Hyun Kim; Seong-Kwan Kim; Dong-Soon Kim; Dan Zhang; Jin-A Park; Hee Yi; Jin-Suk Kim; Ho-Chul Shin
Journal:  Oncol Lett       Date:  2015-03-09       Impact factor: 2.967

Review 4.  Preclinical and clinical role of interleukin-6 in the development of delayed cerebral vasospasm and neuronal cell death after subarachnoid hemorrhage: towards a potential target therapy?

Authors:  Davide Marco Croci; Sivani Sivanrupan; Stefan Wanderer; Guilherme J Agnoletto; Alessio Chiappini; Basil E Grüter; Lukas Andereggen; Luigi Mariani; Philipp Taussky; Serge Marbacher
Journal:  Neurosurg Rev       Date:  2021-08-27       Impact factor: 2.800

5.  Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice.

Authors:  Henry W Murray
Journal:  Infect Immun       Date:  2008-06-23       Impact factor: 3.441

Review 6.  Recent advances in neutralizing the IL-6 pathway in arthritis.

Authors:  Charles J Malemud
Journal:  Open Access Rheumatol       Date:  2009-10-05

Review 7.  Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.

Authors:  Alti Dayakar; Sambamurthy Chandrasekaran; Suresh V Kuchipudi; Suresh K Kalangi
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.